Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Envoy Medical, Inc. (NASDAQ: COCH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a hearing health business focused on fully implanted hearing devices. Envoy Medical files reports and registration statements that describe its Esteem® fully implanted active middle ear implant (FI-AMEI), the investigational fully implanted Acclaim® cochlear implant, its financial condition, capital structure, and key risks.
Through its Forms 10-Q and 10-K, Envoy Medical presents detailed financial statements and management discussion of operations, including net revenues from the Esteem FI-AMEI and related components, research and development expenses tied to the Acclaim pivotal clinical trial, and general and administrative costs associated with operating as a public company. These periodic reports also discuss liquidity, capital resources, and risk factors relevant to investors evaluating COCH.
Current reports on Form 8-K capture material events such as FDA approval to expand the pivotal clinical trial for the fully implanted Acclaim cochlear implant to its final stage, notices and determinations related to Nasdaq listing requirements, equity and warrant financing transactions, and quarterly earnings announcements. Proxy materials on Schedule 14A outline shareholder proposals, including approvals related to warrant issuances under Nasdaq rules, and provide additional context on the company’s capital raising activities.
Envoy Medical has also filed registration statements on Form S-1 and Form S-3 covering offerings of Class A common stock, pre-funded warrants, and the resale of shares underlying private placement warrants. These documents describe the company as an emerging growth company and a smaller reporting company, and they summarize its business focus on fully implanted hearing technologies, including the Esteem FI-AMEI and the investigational Acclaim cochlear implant.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, such as key changes in revenues and expenses, updates on the Acclaim clinical trial, new financing arrangements, and material listing or regulatory developments. Users can quickly review Forms 10-K and 10-Q for an overview of Envoy Medical’s financial performance, scan 8-K filings for significant events, and examine registration statements and proxy materials for details on securities offerings and shareholder approvals, all with real-time updates from the SEC’s EDGAR system.
Envoy Medical, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The company states that the rest of the registration statement is unchanged and has been omitted from this amendment.
The amendment primarily adds or updates exhibits, including forms of warrants and a securities purchase agreement related to the planned offering, various employment and incentive plan documents, debt and forward purchase agreements, and an engagement letter with H.C. Wainwright & Co., LLC. Signature pages confirm authorization by the chief executive officer and directors.
Envoy Medical, Inc. reported that Interim CFO Robert Potashnick received a grant of stock options on February 5, 2026. The award covers 15,000 options to purchase Class A common stock at an exercise price of $0.53 per share, held directly.
The vesting schedule is structured so that 3,750 options vest on February 5, 2027, with the remaining 11,250 options vesting pro rata on the 5th of each month over the following 36 months. This aligns the Interim CFO’s compensation with longer-term company performance.
Envoy Medical, Inc. Chief Executive Officer Brent T. Lucas reported a new stock option grant. On 02/05/2026, he received 200,000 stock options to buy Class A Common Stock at an exercise price of $0.53 per share, granted at no cost.
According to the vesting schedule, options to purchase 50,000 shares vest on 02/05/2027, and 150,000 additional shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Following this grant, he holds 234,590 Class A Common shares, 879,749 previously granted stock options, and 110,987 warrants, all held directly.
Envoy Medical, Inc. is conducting a primary offering registering up to 47,169,811 shares of Class A common stock, multiple series of accompanying warrants, and up to 125,943,394 shares issuable upon exercise of those warrants. The company is selling the stock and associated Series A-1 and Series A-2 common warrants on a reasonable best efforts basis through H.C. Wainwright at an assumed combined public offering price of $0.53 per share and accompanying warrants. Pre-funded warrants are available for investors constrained by 4.99% or 9.99% beneficial ownership limits, and placement agent warrants cover up to 3,301,886 additional shares. Envoy estimates net proceeds of approximately $23.0 million, expects continued net losses as it advances pivotal trials and FDA review of its fully implanted Acclaim cochlear implant, and warns of Nasdaq listing risks, going-concern uncertainty, and substantial dilution for existing shareholders.
Envoy Medical, Inc. filed a Form S-1 for a primary, reasonable best efforts offering of Class A Common Stock and pre-funded warrants, with all net proceeds going to the company. The securities will be priced with investors and the placement agent based on market conditions, and pre-funded warrants are structured so investors do not exceed 4.99% or 9.99% ownership limits. Envoy had 28,934,960 shares of Common Stock outstanding as of December 15, 2025.
The company is a hearing health developer focused on its fully implanted Acclaim cochlear implant, which has FDA Breakthrough Device Designation and is in a pivotal clinical trial whose second stage was cleared by the FDA on October 3, 2025. Envoy reported net losses of $17.2 million for the nine months ended September 30, 2025 and has an accumulated deficit of $305.7 million, and its auditors have raised substantial doubt about its ability to continue as a going concern. Recent registered direct offerings in September and October 2025 raised about $6.5 million in gross proceeds, and the company faces Nasdaq compliance pressures related to both minimum market value of listed securities and minimum bid price.
Envoy Medical, Inc. is providing an updated investor presentation that its management may use, with possible modifications, in meetings with current and potential investors. The presentation is attached as Exhibit 99.1 and includes forward-looking statements, with related risks and uncertainties described in the presentation. This information is being furnished under Regulation FD and is not deemed filed or incorporated into other securities law filings unless specifically referenced.
Envoy Medical, Inc. director Mona Chetan Patel reported changes in her holdings on a Form 4. On 12/03/2025 she acquired 25,000 stock options, each with an exercise price of $0.813, exercisable starting 05/01/2026 and expiring 12/03/2035, covering 25,000 shares of Class A common stock. She also beneficially owns 20,000 shares of Class A common stock directly and holds 25,000 stock options with a $2.4 exercise price expiring 10/15/2033. The filing notes that options to purchase 6,250 shares vest on 10/15/2024, with the remaining 18,750 shares vesting pro rata on the 15th of each month for 36 months.
Envoy Medical, Inc. (COCH) reports that Nasdaq has notified the company its Class A common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, after trading below that level for 30 consecutive business days. The stock remains listed for now.
Envoy has 180 calendar days, until May 18, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it qualifies, the company may receive an additional 180‑day period and could use measures such as a reverse stock split to address the deficiency. Failure to regain or maintain compliance could lead to a Nasdaq delisting determination, which Envoy could appeal. The company states it intends to monitor its share price and consider available options.
Envoy Medical (COCH) filed its Q3 2025 10-Q, reporting net revenues of $42 thousand and an operating loss of $5.708 million. Net loss was $6.482 million, or $0.35 per share. Cash was $3.556 million as of September 30, 2025.
The company eliminated related-party debt via a satisfaction agreement, recording a $27.879 million capital contribution to additional paid-in capital and improving total stockholders’ deficit to $7.661 million. Management states that recurring losses and limited cash raise substantial doubt about the company’s ability to continue as a going concern.
During the quarter, Envoy completed a registered direct offering of 1,908,402 shares for gross proceeds of $2.5 million and issued 5,725,206 Investor Warrants, recognized as a liability measured at fair value. An at-the-market program added $414 thousand year-to-date. The FDA granted an IDE in October 2024 to begin a pivotal study of the fully implanted Acclaim cochlear implant, while the Esteem device continues to generate modest revenue.
Envoy Medical (COCH) furnished an Item 2.02 Form 8-K announcing it issued a press release with financial results for its third fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The disclosure is furnished, not filed, and is therefore not subject to Section 18 liabilities or incorporation by reference.